L’Oréal has submitted to the shareholders of Holding STRP (Société des Thermes de La Roche-Posay) an irrevocable offer for the acquisition of the totality of the shares of the company.

WHO: Created in 1921, Société des Thermes de La Roche-Posay is the first thermal station in Europe exclusively dedicated to treating dermatological diseases. The thermal water of La Roche-Posay has therapeutic anti-inflammatory, healing, and soothing properties to treat skin diseases (eczema, psoriasis, burn scars, and cutaneous side effects of cancer treatments). Recommended by over 90,000 dermatologists worldwide, La Roche-Posay creates skincare for sensitive skin, formulated with thermal water. The first dermo-cosmetic brand worldwide, its key product ranges are: Lipikar (dry skin), Anthélios (photoprotection), Effaclar (acne), Tolériane (sensitive skin), and Cicaplast (skin repair).

IN THEIR OWN WORDS: Laetitia Toupet, International General Manager of La Roche-Posay, said “This acquisition project will enable us to sustain and reinforce the dermatologic position of La Roche-Posay by developing the existing indications and making the thermal station a flagship for the brand.”

DETAILS:

• La Roche-Posay is part of L’Oréal’s Active Division brand.
• In 2017, more than 7,500 patients have benefited from the thermal activity, generating 3.6 million euros of sales.
• The project foresees the prior carve-out of the hotel business to the current shareholders of Holding STRP and the attribution of exclusive negotiation rights to L’Oréal.